Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
UTHR

United Therapeutics Corp

UTHR

241.65USD-0.42 (-0.17%)Market Closed
Watchlist

Market Summary

USD241.65-0.42
Market Closed
-0.17%

UTHR Alerts

  • 1 major insider sales recently.

UTHR Stock Price

View Fullscreen

UTHR RSI Chart

UTHR Valuation

Market Cap

11.4B

Price/Earnings (Trailing)

12.64

Price/Sales (Trailing)

5.16

EV/EBITDA

8.1

Price/Free Cashflow

14.88

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

52.98%

Return on Equity

16.11%

Return on Assets

13.04%

Free Cashflow Yield

6.72%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

18.1%

Revenue Q/Q

2.16%

UTHR Earnings

Earnings (TTM)

899.8M

Earnings Y/Y

11.83%

Earnings Q/Q

3.24%

Price Action

52 Week Range

204.44283.09
(Low)(High)

Last 7 days

0.9%

Last 30 days

5.1%

Last 90 days

7.5%

Trailing 12 Months

-12.6%

How does UTHR drawdown profile look like?

UTHR Financial Health

Current Ratio

8.68

UTHR Investor Care

Shares Dilution (1Y)

3.11%

Diluted EPS (TTM)

18.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.0B2.1B2.2B0
20221.8B1.8B1.9B1.9B
20211.5B1.6B1.7B1.7B
20201.4B1.4B1.4B1.5B
20191.6B1.5B1.5B1.4B
20181.7B1.7B1.7B1.6B
20171.6B1.6B1.7B1.7B
20161.5B1.6B1.6B1.6B
20151.3B1.3B1.4B1.5B
20141.2B1.2B1.2B1.3B
2013957.0M1.0B1.1B1.1B
2012784.9M826.7M867.4M916.1M
2011629.5M678.5M711.7M743.2M
2010405.1M455.8M527.2M592.9M
20090335.9M362.4M358.9M
2008000281.5M

Latest Insider Trading transactions for UTHR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
giltner richard
back to issuer
-1,203,650
240
-5,000
-
Dec 01, 2023
giltner richard
acquired
440,150
88.03
5,000
-
Nov 29, 2023
olian judy d.
gifted
-
-
-950
-
Nov 16, 2023
mahon paul a
acquired
706,560
117
6,000
evp & general counsel
Nov 16, 2023
mahon paul a
sold
-1,359,590
226
-6,000
evp & general counsel
Nov 07, 2023
patusky christopher
acquired
176,060
88.03
2,000
-
Nov 07, 2023
patusky christopher
back to issuer
-460,880
230
-2,000
-
Nov 02, 2023
mahon paul a
acquired
706,560
117
6,000
evp & general counsel
Nov 02, 2023
mahon paul a
sold
-1,354,550
225
-6,000
evp & general counsel
Oct 19, 2023
mahon paul a
acquired
706,560
117
6,000
evp & general counsel

1–10 of 50

Which funds bought or sold UTHR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
15.27
2,814,440
18,497,800
0.01%
Dec 01, 2023
B. Riley Wealth Advisors, Inc.
new
-
218,642
218,642
0.01%
Nov 27, 2023
USA FINANCIAL FORMULAS
unchanged
-
1,162
51,272
0.08%
Nov 27, 2023
TRUST CO OF VERMONT
new
-
10,616
10,616
-%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-71.61
-33,101,800
13,552,400
0.01%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
405,888
405,888
0.01%
Nov 22, 2023
KBC Group NV
unchanged
-
-
181,000
-%
Nov 22, 2023
Public Sector Pension Investment Board
unchanged
-
40,960
1,806,960
0.01%
Nov 21, 2023
COMERICA BANK
added
2,697
35,366,200
35,368,200
0.18%
Nov 17, 2023
Diversified Trust Co
new
-
286,403
286,403
0.01%

1–10 of 40

Latest Funds Activity

Are funds buying UTHR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own UTHR
No. of Funds

Schedule 13G FIlings of United Therapeutics Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 10, 2023
wellington management group llp
10.01%
4,688,824
SC 13G/A
Mar 08, 2023
blackrock inc.
10.2%
4,726,986
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
6.3%
2,865,000
SC 13G/A
Feb 13, 2023
renaissance technologies llc
5.14%
2,344,492
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.83%
4,480,719
SC 13G/A
Feb 06, 2023
wellington management group llp
5.64%
2,569,263
SC 13G
Feb 02, 2023
rothblatt martine a
8.0%
3,919,603
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
4,510,211
SC 13G/A
Feb 11, 2022
renaissance technologies llc
6.48%
2,917,191
SC 13G/A

Recent SEC filings of United Therapeutics Corp

View All Filings
Date Filed Form Type Document
Dec 07, 2023
144
Notice of Insider Sale Intent
Dec 07, 2023
4
Insider Trading
Dec 04, 2023
4
Insider Trading
Dec 04, 2023
SC TO-T/A
SC TO-T/A
Dec 01, 2023
4
Insider Trading
Nov 29, 2023
8-K
Current Report
Nov 17, 2023
4
Insider Trading
Nov 16, 2023
144
Notice of Insider Sale Intent
Nov 13, 2023
SC TO-T
SC TO-T
Nov 08, 2023
4
Insider Trading

UTHR Fair Value

Loading...

Peers (Alternatives to United Therapeutics Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
30.9B
-
5.25% 401813.88%
-3.6K
218.4K
- -102.45%
30.5B
10.7B
8.54% -55.34%
-8.79
2.86
-53.67% -129.46%
22.2B
1.7B
4.15% -23.37%
-43.62
12.9
79.37% 56.87%
17.9B
2.3B
11.05% -8.44%
121.62
7.74
15.05% 75.21%
12.4B
3.6B
0.84% -34.33%
29.1
3.43
8.35% -51.49%
MID-CAP
7.6B
272.9M
35.37% 34.74%
-12.51
27.78
141.38% 4.43%
5.9B
-
14.36% 263.35%
-10.02
48.33
54.84% -12.96%
3.6B
631.9M
-7.32% 48.57%
-24.01
5.65
23.54% 31.53%
3.3B
223.4M
11.28% -10.13%
-16.47
14.87
- -26.24%
2.6B
240.7M
-10.83% -25.35%
-12.82
10.93
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
11.36% -14.92%
24.59
4.38
81.69% -7.29%
656.6M
1.0B
-22.00% -67.89%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.23%
-0.61
15.6
-44.11% 50.48%
39.5M
-
376.67% 112.17%
-0.61
-
- -29.23%
23.3M
-
25.24% 3980.68%
-0.49
-
- -13.74%

United Therapeutics Corp News

Latest updates
Nasdaq08 Dec 202308:43 pm66 minutes ago
Yahoo Finance08 Dec 202302:05 pm7 hours ago
Knox Daily23 Nov 202308:00 am15 days ago
Yahoo Finance01 Nov 202307:00 am37 days ago
The Business Journals01 Nov 202307:00 am37 days ago
Morningstar30 Oct 202307:00 am39 days ago
The Business Journals30 Oct 202307:00 am39 days ago
BNN Bloomberg10 Oct 202304:31 pm59 days ago
Yahoo Finance08 Sep 202307:00 am3 months ago
The Business Journals16 May 202307:00 am6 months ago
TheStreet09 Mar 202308:00 am9 months ago
Marketscreener.com22 Feb 202308:00 am9 months ago
StockNews.com21 Feb 202302:08 pm9 months ago
Markets Insider07 Feb 202308:00 am10 months ago
The Business Journals02 Nov 202207:00 am13 months ago

Financials for United Therapeutics Corp

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue2.2%609597507492516467462415445447379385380362356311402374363381413
Costs and Expenses-0.2%2822832233162022651742452162244443201592221902482181521,019250263
  S&GA Expenses-1.8%12813087.00-98.0014279.00-109113---------66.00-
  R&D Expenses-4.8%85.0089.0083.0094.0066.0094.0069.0083.0079.0074.0030412669.0090.0073.0011486.0086.00897139101
EBITDA Margin-100.0%-0.58*0.52*0.53*0.53*0.49*0.53*0.39*0.38*0.41*0.38*0.48*0.48*0.44*0.52*-0.05*-----
Interest Expenses5.4%16.0015.0014.0012.009.006.005.005.005.005.005.005.005.006.008.0010.0012.0012.0010.004.004.00
Income Taxes10.8%84.0076.0051.0047.0073.0035.0069.0028.0042.0044.004.0016.0048.0027.0034.0016.0035.0045.00-15627.0034.00
Earnings Before Taxes5.0%35233529217931315130914120421733.0011421913417268.00167250-65092.00140
EBT Margin-100.0%-0.53*0.47*0.49*0.49*0.45*0.49*0.35*0.34*0.37*0.33*0.43*0.42*0.38*0.46*-0.11*-----
Net Income3.2%26825924113223911624011216317328.0099.0017110713853.00132205-49465.00107
Net Income Margin-100.0%-0.41*0.37*0.38*0.38*0.35*0.39*0.28*0.28*0.30*0.27*0.35*0.33*0.30*0.37*-0.07*-----
Free Cashflow-100.0%-62.0033489.0019011027510416213279.0011423514620278.00-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets5.1%7,0246,6816,3466,0455,7825,5435,3605,1695,0494,8454,6414,6154,4114,2194,0263,9134,0003,8993,7273,4013,412
  Current Assets7.6%3,4593,2133,1933,3803,0562,6842,5872,3242,3862,3182,0142,1671,8681,8941,8461,8651,9332,1401,9431,7681,609
    Cash Equivalents3.8%1,1081,0671,164961967795813895909942832739670685875738720881791669656
  Inventory1.0%10410310310291.0090.0088.0094.0097.0090.0092.0087.0088.0090.0092.0093.0094.0097.0096.00101101
  Net PPE5.7%992939897862841791784781727716714732736744739739678709701700665
Liabilities3.2%1,3121,2701,2231,2481,2191,2251,1841,2101,2191,2051,1961,2201,1281,1261,0771,1331,2841,3321,389593700
  Current Liabilities100.9%744370325343316332293305320311302323259255207463470464270277372
Shareholder's Equity5.6%5,7125,4115,1234,7974,5624,3184,1763,9593,8303,6403,4453,3953,2833,0942,9492,7802,7162,5582,3192,7892,693
  Retained Earnings4.8%5,8105,5425,2835,0424,9104,6714,5554,3154,2034,0403,8683,8393,7403,5693,4623,3253,2733,1402,9353,4353,370
  Additional Paid-In Capital1.1%2,5242,4982,4572,3882,3152,2922,2542,2452,2262,1972,1732,1492,1262,1052,0682,0482,0262,0021,9681,9401,924
Shares Outstanding0.1%47.0047.0047.0046.0046.0045.0045.0045.0045.0045.0045.0045.0044.0044.0044.0044.0044.0044.0044.0044.0044.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations225.7%34610637512825912728917518614890.00126251164215103185133-62785.00238
  Share Based Compensation52.9%21.0014.00-12.4065.00-2.4066.00-21.1045.0025.0029.0040.0094.00-12.5052.0031.0030.0024.00-37.2029.003.0051.00
Cashflow From Investing-37.9%-313-227-221-189-94.00-169-359-195-235-48.90-6.30-63.80-271-375-27.6066.00-298-42.60-60.30-72.20-329
Cashflow From Financing-69.2%8.0025.0049.0056.007.0024.00-11.008.0017.0011.0010.006.006.0022.00-50.20-150-48.300.008090.002.00

UTHR Income Statement

2023-09-30
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Total revenues$ 609.4$ 516.0$ 1,712.8$ 1,444.8
Operating expenses:    
Cost of sales70.137.2186.592.8
Research and development84.766.1256.6229.0
Selling, general, and administrative127.698.4344.9318.9
Total operating expenses282.4201.7788.0640.7
Operating income327.0314.3924.8804.1
Interest income45.313.3111.724.4
Interest expense(15.6)(9.2)(44.2)(20.1)
Other expense, net(4.9)(5.9)(13.4)(34.9)
Impairment of investment in privately-held company0.00.00.0(1.7)
Total other income (expense), net24.8(1.8)54.1(32.3)
Income before income taxes351.8312.5978.9771.8
Income tax expense(84.2)(73.2)(211.2)(176.6)
Net income$ 267.6$ 239.3$ 767.7$ 595.2
Net income per common share:    
Basic (in dollars per share)$ 5.71$ 5.26$ 16.44$ 13.14
Diluted (in dollars per share)$ 5.38$ 4.91$ 15.48$ 12.35
Weighted average number of common shares outstanding:    
Basic (in shares)46.945.546.745.3
Diluted (in shares)49.748.749.648.2

UTHR Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,107.7$ 961.2
Marketable investments1,767.81,877.5
Accounts receivable, no allowance for 2023 and 2022258.6220.4
Inventories, net104.3102.0
Other current assets220.5219.2
Total current assets3,458.93,380.3
Marketable investments2,060.81,316.2
Goodwill and other intangible assets, net44.444.5
Property, plant, and equipment, net992.2861.5
Deferred tax assets, net325.6327.7
Other non-current assets141.7114.3
Total assets7,023.66,044.5
Current liabilities:  
Accounts payable and accrued expenses333.4229.9
Line of credit (current)300.00.0
Share tracking awards plan40.680.8
Other current liabilities70.132.5
Total current liabilities744.1343.2
Line of credit (non-current)500.0800.0
Other non-current liabilities67.4104.6
Total liabilities1,311.51,247.8
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued0.00.0
Common stock, par value $.01, 245,000,000 shares authorized, 73,600,427 and 72,651,280 shares issued, and 46,981,211 and 46,032,064 shares outstanding as of September 30, 2023 and December 31, 2022, respectively0.70.7
Additional paid-in capital2,524.32,388.4
Accumulated other comprehensive loss(43.7)(55.5)
Treasury stock, 26,619,216 shares as of September 30, 2023 and December 31, 2022(2,579.2)(2,579.2)
Retained earnings5,810.05,042.3
Total stockholders’ equity5,712.14,796.7
Total liabilities and stockholders’ equity$ 7,023.6$ 6,044.5
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
 CEO
 WEBSITEwww.unither.com
 EMPLOYEES985

United Therapeutics Corp Frequently Asked Questions


What is the ticker symbol for United Therapeutics Corp? What does UTHR stand for in stocks?

UTHR is the stock ticker symbol of United Therapeutics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of United Therapeutics Corp (UTHR)?

As of Thu Dec 07 2023, market cap of United Therapeutics Corp is 11.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart. The fair value of United Therapeutics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of United Therapeutics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTHR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is United Therapeutics Corp a good stock to buy?

The fair value guage provides a quick view whether UTHR is over valued or under valued. Whether United Therapeutics Corp is cheap or expensive depends on the assumptions which impact United Therapeutics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTHR.

What is United Therapeutics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, UTHR's PE ratio (Price to Earnings) is 12.64 and Price to Sales (PS) ratio is 5.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTHR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on United Therapeutics Corp's stock?

In the past 10 years, United Therapeutics Corp has provided 0.103 (multiply by 100 for percentage) rate of return.